Curatis Holding AG
20.42
CHF
+7.86
(+62.54%)
ISIN
CH1330780979
Return %
Stock
S&P 500
1Y
88.96
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Roland Rutschmann
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Weierweg 7 Liestal BL Switzerland 4410
- IPO Date
- Oct 18, 1999
- Website
- curatis.com
- Similar Companies
- Business
- Curatis Holding AG, a Switzerland-based specialty pharmaceutical company, conducts distribution and drug development activities focused on orphan and ultra-orphan indications in Europe, with headquarters in Switzerland and a public listing on SIX Swiss Exchange (ticker CURN.SW). The group combines a Swiss-focused distribution platform with a development pipeline and seeks growth through expanding its product portfolio and geographic reach in Europe. Main Products and Services - Specialty pharmaceutical distribution: exclusive Swiss distribution rights for more than 30 drugs developed by third-party partners, including orphan and specialty medicines; broad distribution network within Switzerland with potential expansion into larger European markets (Germany, France, UK, Italy) [MarketScreener profile] [Ad hoc statements] - Drug development and acquisition: in-licensing, acquiring, and advancing clinical-stage programs with a focus on orphan indications; management of a pipeline of projects in advanced and late clinical development, including proprietary platforms such as KIN001 (historical reference) with potential future applications [MarketScreener profile] [Ad hoc press releases] - Commercial operations: commercialization of therapeutic candidates and marketed products, leveraging Curatis AG as the operating subsidiary to drive sales, marketing, and regulatory activities in its core markets [Ad hoc announcements] Latest Major Company Changes - Corporate restructuring and rebranding: in 2024, Kinarus Therapeutics Holding AG merges with Curatis AG, forming Curatis Holding AG and aligning the group’s identity with its expanded distribution and orphan-drug development focus; the combination creates a listed specialty pharmaceuticals group with Swiss distribution strength and an innovative pipeline [PharmiWeb press release; MarketScreener profiles] - Strategic expansion and partnerships: the group pursues strategic alliances and distribution collaborations to broaden its Swiss base and to enter larger European markets (Germany, France, UK, Italy) for orphan and specialty products; partnerships aim to bolster the product portfolio and geographic reach [Ad hoc press releases; MarketScreener] - Financial and operational updates: Curatis reports growth in core distribution activities and organises financial disclosures with annual and interim results; notable milestones include revenue growth in H1 2024 and continued development milestones for pipeline programs; AGMs approve strategic proposals including focus on rare diseases and governance continuity [FinanzNachrichten coverage; AGM notices; MarketScreener] Additional Context - Industry and segments: specialty pharmaceuticals, orphan/ultra-orphan drug development, pharmaceutical distribution, clinical-stage drug programs - Target markets: Switzerland as the base with strategic expansion into Germany, France, United Kingdom, Italy and broader European markets - Geographic footprint: primarily Switzerland; planned expansion into major European markets - Founding year and headquarters: established via the 2024 combination; headquarters located in Switzerland - Corporate structure: wholly owned operating subsidiary Curatis AG drives distribution and development activities; listed corporate structure on SIX Swiss Exchange under ticker CURN.SW Note: This description reflects publicly disclosed information up to early 2025 and through 2026 coverage, capturing the company’s core activities, product focus, and recent strategic changes while emphasizing its dual model of specialty drug distribution and orphan-drug development.